Anesthesiology · Postoperative Nausea and VomitingTrial Updateclinicalmid-term

Wrist-Ankle Acupuncture Shows Promise for Preventing Postoperative Nausea in High-Risk Patients

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/7/2026, 6:34:12 PM

Assessment confidence: 68% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The trial results on wrist-ankle acupuncture for preventing postoperative nausea and vomiting (PONV) could shift treatment paradigms in anesthesiology. If effective, this non-pharmacological approach may challenge existing antiemetic therapies, necessitating a strategic reevaluation by pharma companies in this therapeutic area. Regulatory context from MHRA (MHRA authorises gemcitabine delivery system for adults with BCG-unresponsive high-risk non-muscle invasive bladder cancer) supports the near-term read. Assessment grounded in 23 ranked evidence items (12 high-relevance).

Strategic Assessment

Pharma companies may need to consider integrating non-pharmacological approaches in their PONV management strategies or face competition from alternative therapies. The strongest clinical anchor is Carbohydrate Fluids and Post Operative Nausea and Vomiting (ClinicalTrials.gov), moderate corpus alignment. In Anesthesiology · Postoperative Nausea and Vomiting, 7 regulatory and 3 competitive items passed relevance filtering for antiemetic drug manufacturers.

Competitive Pressure

The most relevant competitive pressure comes from Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial (Bristol Myers Squibb) — sponsor/company relevance (bristol myers squibb). Secondary pressure from Phase III Trial of Afimkibart Shows Promise for Moderately to Severely Active Crohn's Disease.

Regulatory Outlook

Regulatory risk is concentrated around MHRA authorises gemcitabine delivery system for adults with BCG-unresponsive high-risk non-muscle invasive bladder cancer (MHRA). Regulatory pathway relevance (bla). Relevant agencies in corpus: MHRA, FDA. As a non-pharmacological intervention, wrist-ankle acupuncture may not face the same regulatory hurdles as new drug approvals, but its adoption will depend on clinical validation.

Key Opportunities

Should wrist-ankle acupuncture prove effective, it could capture market share from traditional antiemetic drugs, impacting revenue streams for companies reliant on these products.
How we engage and involve patients and the public in our regulatory decision-making.
Upside for antiemetic drug manufacturers may improve if An Open-Label, Pilot Clinical Trial To Test The Safety And Feasibility Of A Suspension of Freeze-dried Microbiota In Patients Undergoing Colon Resection (ClinicalTrials.gov) delivers favorable follow-through.
Upside for antiemetic drug manufacturers may improve if Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma (ClinicalTrials.gov) delivers favorable follow-through.
Pharma companies may need to consider integrating non-pharmacological approaches in their PONV management strategies or face competition from alternative therapies.

What Would Change This Assessment

This becomes more urgent if Monitor further results from this trial and any subsequent studies on acupuncture's efficacy in PONV prevention.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

MHRA authorises gemcitabine delivery system for adults with BCG-unresponsive high-risk non-muscle invasive bladder cancer
MHRAhigh relevance
Regulatory pathway relevance (bla)
FDA document
View source
FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Condition-Specific Meeting Reports and Other Information Related to Patients' Experience
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Preventing Accidental Apoquel Chewable Overdoses
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
FDA Alerts Health Care Providers to Cases of Neurologic Complications from General Anesthesia Linked to Genetic Variant in Patients of Maternal Venezuelan Ancestry
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Opportunities for patients and the public to be involved in the work of the MHRA
MHRAhigh relevance
Moderate corpus alignment
FDA document
View source

Carbohydrate Fluids and Post Operative Nausea and Vomiting
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
An Open-Label, Pilot Clinical Trial To Test The Safety And Feasibility Of A Suspension of Freeze-dried Microbiota In Patients Undergoing Colon Resection
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Dexamethasone Palmitate for PONV After Minimally Invasive Endoscopic Surgery
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
Bristol Myers Squibbhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Phase III Trial of Afimkibart Shows Promise for Moderately to Severely Active Crohn's Disease
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Psilocybin Shows Promise in Preventing Relapse in Alcohol Use Disorder with Depression
Humanexa Signalsmedium relevance
Moderate corpus alignment

Wrist-Ankle Acupuncture on Postoperative Nausea and Vomiting Prophylaxis in High-Risk Female Patients: A Pragmatic, Randomized, Single-Blind, Sham-Controlled Trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Impact of oliceridine versus sufentanil on postoperative nausea and vomiting in patients undergoing thyroid surgery: a prospective, double-blind, randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of sub-anesthetic doses of esketamine on immune function and postoperative negative emotions in acoustic neuroma patients: a randomized clinical trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effect of different liposomal bupivacaine concentrations in ultrasound-guided superior trunk block on postoperative analgesia and mobility: a randomized double-blind controlled trial protocol for shou
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Thoracic paravertebral block with different doses of liposomal bupivacaine versus ropivacaine for postoperative analgesia in single-port thoracoscopic lung surgery: a randomized clinical trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Oro-esophageal feeding for tracheostomized patients with severe traumatic brain injury: a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

antiemetic drug manufacturers

Commercial impact

medium

Should wrist-ankle acupuncture prove effective, it could capture market share from traditional antiemetic drugs, impacting revenue streams for companies reliant on these products.

Regulatory impact

low

As a non-pharmacological intervention, wrist-ankle acupuncture may not face the same regulatory hurdles as new drug approvals, but its adoption will depend on clinical validation.

What to watch

Monitor further results from this trial and any subsequent studies on acupuncture's efficacy in PONV prevention.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.